Li Zhang

Li Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
JLJuan Liu
Juan Liu
XMXiaoli Ma
Xiaoli Ma
LCLeiyu Cao
Leiyu Cao
YWYu Wei
Yu Wei
YGYan Gao
Yan Gao
LZLi Zhang
Li Zhang
Purpose. Esophageal squamous cell cancer (ESCC) is a deadly malignant tumor characterized by an overall 5-year survival rate below 20%, with China accounting for approximately 50% of all cases worldwide. Our previous studies have demonstrated that high integrin-linked kinase (ILK) expression plays a key role in development and progression of ESCC both in vitro and in vivo. Here, we employed the drug repurposing approach to identify a novel FDA-approved anticancer inhibitor against ILK-induced tumorigenesis and progression. Methods. We screened the ZINC15 database and predicted the molecular docking ability among FDA-approved and publicly available drugs to ILK and then performed computational docking and visual inspection analyses of the top 10 ranked drugs. Two computer-based virtual screened drugs were evaluated in vitro for their ability to directly bind purified ILK by surface plasmon resonance. Cytotoxicity of the two candidate drugs was validated in vitro using CCK-8 and LDH assays. Results. We initially selected the top 10 compounds, based on their minimum binding energy to the ILK crystal, after molecular docking and subjected them to further screening. Taking the binding energy of −10 kcal/mol as the threshold, we selected two drugs, namely, nilotinib and teniposide, for the wet-lab experiment. Surface plasmon resonance (SPR) revealed that nilotinib and teniposide had equilibrium dissociation constant (KD) values of 6.410E − 6 and 1.793E − 6, respectively, which were lower than 2.643E − 6 observed in ILK-IN-3 used as the positive control. The IC50 values for nilotinib and teniposide in ESCC cell lines were 40 μM and 200–400 nM, respectively. Results of the CCK-8 assay demonstrated that both nilotinib and teniposide significantly inhibited proliferation of cells ( ). LDH results revealed that both drugs significantly suppressed the rate of cell death ( ). Conclusion. The drug repositioning procedure can effectively identify new therapeutic tools for ESCC. Our findings suggest that nilotinib and teniposide are efficacious inhibitors of ILK and thus have potential to target ILK-mediated signaling pathways for management of ESCC.

29 April 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YKYanliang Kang
Yanliang Kang
WZWanli Zhang
Wanli Zhang
QYQiumin Yu
Qiumin Yu
LGLe Gao
Le Gao
JQJiale Quan
Jiale Quan
WYWenbing Yao
Wenbing Yao

2 May 2022 in Bioengineered
Verified
Journal Article
Open access
TXTing Xu
Ting Xu
XMXiao-Li Ma
Xiao-Li Ma
YWYu Wei
Yu Wei
LCLei-Yu Cao
Lei-Yu Cao
YGYan Gao
Yan Gao
LZLi Zhang
Li Zhang
Recent studies have shown that the expression of integrin-linked kinase (ILK) was related to the occurrence, development, and malignant progression of esophageal squamous cell carcinoma (ESCC). However, research on the relationship between ILK and the chemosensitivity of ESCC has to date not been reported. The present study found that ILK was highly expressed in ESCC cell lines, and the overexpression of ILK in ESCC cells reduced the incidence of cell apoptosis and alleviated the cytotoxicity on cells induced by cisplatin (CDDP). Inversely, ILK knockdown increased CDDP-induced apoptosis and had an inhibitive effect on the malignant phenotype of ESCC, including cell proliferation, invasion, and migration. In addition, ILK knockdown in ESCC cells inhibited the expression of beta (β)-catenin and activated the wingless/integrated (Wnt) signaling pathway. Furthermore, cellular MYC (c-MYC) and Cylin D1 were the target genes of the Wnt signaling pathway. Rescue experiments showed that the overexpression of β-catenin reversed a tumor’s inhibition and apoptosis abilities induced by ILK knockdown. In conclusion, ILK potentially reduced the CDDP sensitivity of ESCC cells by influencing the activity of the Wnt/β-catenin signaling pathway. GRAPHICAL ABSTRACT

9 September 2022 in Medicine
Verified
Journal Article
Open access
NMNuersimanguli Mm Maimaitiming
Nuersimanguli Mm Maimaitiming
XMXiaoli Ma
Xiaoli Ma
YWYu Wei
Yu Wei
LCLeiyu Mm Cao
Leiyu Mm Cao
YGYan Gao Gao
Yan Gao Gao
LZLi Zhang
Li Zhang
Background: To evaluate the role and safety of endostar in cervical cancer by comparing the efficacy and adverse reactions of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma. Methods: The quality of the included literature was evaluated by searching the database for the comparison of endostar combined with concurrent radiotherapy and chemotherapy in cervical cancer patients; objective response rate (ORR) and disease control rate (DCR) were used as the main outcome indicators, and statistical analysis was performed using RevMan5.3 and State15.3 software. Results: A total of 13 studies were included in this study, including 1057 patients with locally advanced cervical cancer, suggesting that endostar combined with chemoradiotherapy can significantly improve the objective response rate (ORR: odds ratio 3.88, 95% confidence interval 2.77–5.45, P < .00001) and disease control rate (DCR: odds ratio 4.43, 95% confidence interval 2.78–7.04; P < .00001), and there was no significant increase in treatment-related adverse reactions. Conclusions: In this meta-analysis, endostar combined with concurrent chemoradiotherapy significantly improved ORR and DCR in patients with locally advanced cervical cancer without increasing toxicity. However, this study only analyzed the short-term efficacy of endostar, and its influence on overall survival and progression-free survival needs to be further verified in large randomized controlled trials with long-term follow-up.

15 August 2025 in Medicine
Verified
Journal Article
Open access
MHMuhetaibaier Hairoula
Muhetaibaier Hairoula
YWYu Wei
Yu Wei
KMKalima Muhetaer
Kalima Muhetaer
XMXiaoli Ma
Xiaoli Ma
LCLeiyu Cao
Leiyu Cao
LZLi Zhang
Li Zhang
Background: The advent of immune checkpoint inhibitors has introduced innovative therapeutic paradigms for the management of human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction cancer (GC/GEJC). However, the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy versus chemotherapy alone in patients with HER2-negative advanced GC/GEJC remain contentious. The comparability among different subgroups is not fully understood, necessitating the identification of optimal patient demographics and the exploration of potential biomarkers. Methods: This study identified 6 Phase III randomized controlled trials evaluating the first-line treatment of HER2-negative GC/GEJC with PD-1 inhibitors in combination with chemotherapy. The primary endpoints include overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), assessed using hazard ratios (HR), relative risk, and their respective 95% confidence intervals (CI). Secondary outcomes are treatment-related adverse events and immune-related adverse events. Prespecified subgroups encompass microsatellite instability, programmed death-ligand 1 (PD-L1) combined positive score (CPS), age, gender, previous surgery, primary location, liver metastases, Eastern Cooperative Oncology Group performance status score, histological subtype, chemotherapy regimen, race, and PD-L1 expression in tumor cells. Results: Incorporating data from 6 randomized controlled trials, this analysis included 6294 adult patients with HER2-negative advanced GC/GEJC. The combined PD-1 inhibitor and chemotherapy regimen significantly improved OS ( HR = 0.79, 95% CI [0.75, 0.84], P < .00001) and PFS ( HR = 0.75, 95% CI [0.70, 0.80], P < .00001), along with enhancing the ORR (relative risk = 1.22, 95% CI [1.15, 1.29], P < .00001). Subgroup analyses revealed benefits in OS, PFS, and ORR for patients with CPS ≥ 1, CPS ≥ 5, and CPS ≥ 10 when treated with first-line PD-1 inhibitors and chemotherapy, with higher PD-L1 expression levels correlating with greater efficacy. Furthermore, patients with high microsatellite instability exhibited a more pronounced extension in OS ( HR = 0.35, 95% CI [0.21, 0.59], P < .0001). However, factors such as age, gender, previous surgery, primary location, liver metastases, Eastern Cooperative Oncology Group performance status score, histological subtype, chemotherapy regimen, race, and PD-L1 expression in tumor cells were not predictive of an OS benefit from PD-1 inhibitors combined with chemotherapy over chemotherapy alone. Regarding safety, the PD-1 inhibitor and chemotherapy combination led to a higher incidence of immune-mediated adverse events, though there was no significant difference in adverse events leading to death. Conclusion: First-line treatment with PD-1 inhibitors combined with chemotherapy surpasses chemotherapy alone in efficacy for patients with HER2-negative advanced GC/GEJC, particularly in those with CPS ≥ 10 or high microsatellite instability, with tolerable adverse events.

28 April 2026 in Anti-Cancer Drugs
Verified
Journal Article
Open access
XMXiaoli Ma
Xiaoli Ma
YWYu Wei
Yu Wei
LCLeiYu Cao
LeiYu Cao
YGYan Gao
Yan Gao
CQChengcheng Qu
Chengcheng Qu
LZLi Zhang
Li Zhang
Integrin-linked kinase (ILK) is a key oncogenic driver in oesophageal squamous cell carcinoma (ESCC). This study evaluated the antitumour effects of the novel ILK inhibitor Nilotinib and explored its downstream mechanisms. In vitro , TE-1 and KYSE150 cells were assessed using Cell Counting Kit-8, lactate dehydrogenase release, colony formation, 5-ehynyl-2 ’ -deoxyuridine incorporation, flow cytometry, Transwell assays, and Western blotting to confirm ILK targeting and determine functional changes. Electron microscopy and fluorescent probes with flow cytometry were used to analyse mitochondrial alterations. In vivo , a nude mouse subcutaneous xenograft model was established to examine tumour growth after peritumoural Nilotinib administration; hematoxylin and eosin staining assessed tissue changes, and immunohistochemistry measured Ki67 and cleaved-caspase 3 expression. ILK overexpression alleviated Nilotinib-induced cytotoxicity, restored proliferation, increased proliferating cell nuclear antigen (PCNA) and Ki67, and reduced cleaved-caspase 3 and cleaved poly(ADP-ribose) polymerase (PARP), supporting ILK as a primary target. Nilotinib dose-dependently inhibited proliferation, invasion, and metastasis while promoting apoptosis, accompanied by downregulation of PCNA, Ki67, [matrix metalloproteinase 2 (MMP2), MMP9, and COX2] and upregulation of cleaved-caspase 3 and cleaved-PARP. In xenografts, Nilotinib significantly reduced tumour size and weight, decreased Ki67, and increased cleaved-caspase 3.RNA sequencing identified autoimmune regulator (AIRE) as a markedly downregulated molecule following Nilotinib treatment. Cycloheximide chase assays indicated accelerated AIRE protein degradation, while MG132 partially rescued AIRE levels, implicating proteasome-dependent degradation. Overall, Nilotinib suppresses ESCC progression by inhibiting ILK and destabilising AIRE, suggesting its potential as a targeted therapy for ILK-positive ESCC.